In addition, when TGF-β inhibitors are actually administered to IC/BPS patients, it would be preferable to inject the TGF-β inhibitor locally into the bladder wall, like Botox injections for intractable overactive bladder. This evidence concerns the gene TGFB1 and overactive bladder.